(Albany, US) September 28, 2026 – DelveInsight’s “Clostridium Difficile Infections Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Clostridium Difficile Infections pipeline landscape. It covers the Clostridium Difficile Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Clostridium Difficile Infections pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding the Clostridium Difficile Infections Treatment Landscape @ https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight
Key Takeaways from the Clostridium Difficile Infections Pipeline Report
DelveInsight’s Clostridium Difficile Infections pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Clostridium Difficile Infections treatment.
The company with a Clostridium Difficile Infections drug candidate in the most advanced stage, i.e., Phase III, is Vedanta Biosciences.
The leading Clostridium Difficile Infections companies include Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, and others.
Promising Clostridium Difficile Infections pipeline therapies include Ibezapolstat, ADS 024, Ridinilazole, RBX7455, Full Spectrum Microbiota, MBK-01, MGB-BP-3, CRS3123, VE303, DNV 3837, LMN 201, IM-01, and others.
Gain in-depth knowledge of key Clostridium Difficile Infections clinical trials, emerging drugs, and market opportunities @ Clostridium Difficile Infections Clinical Trials Assessment
Clostridium Difficile Infections Overview
Clostridium difficile (C. difficile) is a Gram-positive, spore-forming, anaerobic bacillus widely distributed in the intestinal tract of humans and animals and in the environment. In the last decade, the frequency and severity of C. difficile infection have been increasing worldwide, making it one of the most common hospital-acquired infections. Transmission occurs by the fecal-oral route, and the most important risk factors include antibiotic therapy, old age, and hospital or nursing home stay. C. difficile colonizes the large intestine, and healthy adults with an adequate immune response can become asymptomatic carriers. Neonates also have a high asymptomatic carrier rate owing to a lack of intestinal receptors for the bacterium. Antibiotic use alters the microbial flora of the large intestine, rendering it susceptible to infection.
Diarrhea and colitis, the hallmark features of the infection, are caused by clostridial glycosylation exotoxins: toxin A (TcdA), an enterotoxin, and toxin B (TcdB), which is cytotoxic. A few pathological strains produce an additional binary toxin, the role of which is not elucidated. Once intracellular, both toxins inactivate pathways mediated by the Rho family of proteins, resulting in damage to colonocytes, disruption of intercellular tight junctions, and colitis. Toxin A directly activates neutrophils, while both toxins are involved in neutrophil chemotaxis.
Management involves a multi-step approach: discontinuing the inciting antibiotics, isolating the patient, and administering an antibiotic based on severity, usually vancomycin or fidaxomicin. Asymptomatic patients with a positive stool toxin test do not require treatment. Intravenous metronidazole can be used in patients with ileus, where oral delivery would be delayed, whereas vancomycin cannot be given intravenously because it is not secreted into the colon. Surgical intervention, such as subtotal colectomy with rectal preservation, may be required in fulminant colitis with complications such as toxic megacolon, intestinal perforation, and necrotizing colitis.
First recurrence can be treated with a prolonged taper and pulsed vancomycin regimen or with fidaxomicin if vancomycin was used for the initial episode. Second or further recurrences can be treated with a taper and pulsed vancomycin regimen, vancomycin followed by rifaximin, fidaxomicin, or fecal transplantation. Bezlotoxumab, a human monoclonal antibody against C. difficile toxin, has been approved for managing recurrent infections, with a clinical study showing positive outcomes. Fecal transplantation, in which stool from a healthy donor is introduced into the intestinal tract of a person with disrupted microbial balance, has reported an 80% to 90% success rate in reducing recurrence.
Clostridium Difficile Infections Emerging Drugs Profile
VE303: Vedanta Biosciences
VE303 is a potential first-in-class live biotherapeutic product candidate being developed by Vedanta Biosciences to prevent recurrence of Clostridioides difficile infection (CDI). It consists of a rationally designed, defined bacterial consortium of 8 strains of clonal human commensal bacteria selected for their ability to provide colonization resistance to C. difficile. VE303 is administered orally in capsules and produced under cGMP conditions from pure, clonal bacterial cell banks, yielding a standardized drug product. In a Phase II study, high-dose VE303 met its primary endpoint of preventing CDI recurrence at eight weeks in patients at high risk of recurrence, and it was generally well tolerated. Vedanta is currently enrolling patients into a pivotal Phase III registrational study called RESTORATiVE303 to evaluate the efficacy and safety of VE303 for the prevention of recurrent CDI.
Ibezapolstat: Acurx Pharmaceuticals
Ibezapolstat (formerly ACX-362E) is Acurx’s lead antibiotic candidate and the first in a new class of Pol IIIC inhibitors in clinical development to treat C. difficile infections. In June 2018, the U.S. FDA designated ibezapolstat a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI, making it eligible for incentives under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, the FDA granted it Fast Track designation. The CDC has designated C. difficile an urgent threat, highlighting the need for new antibiotics. The drug is currently in the Phase II stage of development for Clostridium Difficile Infections.
The Clostridium Difficile Infections Pipeline Report Provides Insights Into
Detailed insights about companies developing therapies for Clostridium Difficile Infections, with aggregate therapies developed by each company.
Therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Clostridium Difficile Infections treatment.
Targeted therapeutics development by Clostridium Difficile Infections companies, with respective active and inactive (dormant or discontinued) projects.
Clostridium Difficile Infections drugs under development by stage of development, route of administration, product type, and molecule type.
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and financing details for future advancement of the Clostridium Difficile Infections market.
Uncover critical updates on therapeutic innovations and their potential impact on patients @ Clostridium Difficile Infections Unmet Needs
Clostridium Difficile Infections Companies
Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, and others.
The Clostridium Difficile Infections pipeline report provides the therapeutic assessment of pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Clostridium Difficile Infections products have been categorized under various Molecule types such as:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Clostridium Difficile Infections Pipeline! @ Clostridium Difficile Infections Market Drivers and Barriers, and Future Perspectives
Scope of the Clostridium Difficile Infections Pipeline Report
Coverage: Global
Clostridium Difficile Infections Companies: Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, and others.
Clostridium Difficile Infections Pipeline Therapies: Ibezapolstat, ADS 024, Ridinilazole, RBX7455, Full Spectrum Microbiota, MBK-01, MGB-BP-3, CRS3123, VE303, DNV 3837, LMN 201, IM-01, and others.
Clostridium Difficile Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Clostridium Difficile Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the Full Clostridium Difficile Infections Pipeline Analysis Today! @ Clostridium Difficile Infections Drugs and Companies
Table of Contents
Introduction
Executive Summary
Clostridium Difficile Infections: Overview
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Clostridium Difficile Infections – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Mid Stage Products (Phase II)
Early Stage Products (Phase I)
Preclinical and Discovery Stage Products
Inactive Products
Clostridium Difficile Infections Key Companies
Clostridium Difficile Infections Key Products
Clostridium Difficile Infections – Unmet Needs
Clostridium Difficile Infections – Market Drivers and Barriers
Clostridium Difficile Infections – Future Perspectives and Conclusion
Clostridium Difficile Infections Analyst Views
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight
